Skip to main content
Amylyx logo
Amylyx logo

Powered by people

At our core, we are collaborators who strive to be partners of choice to the communities that we’re humbled to work alongside and in service of. Our trial designs rely on the input of clinical leaders, advocacy groups, and broader disease communities.

That means that our science is powered by people: Amylyx employees, clinical trial site investigators, and clinical trial participants who all share a commitment to drive innovation. If you're interested in enrolling in an Amylyx clinical trial, speak with your physician to learn more. Your physician can help you decide if a clinical trial is right for you.

Logo for Amylyx' clinical trial named Lucidity.

The LUCIDITY trial (NCT06747468) will be a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery.

ABOUT PBH
Logo for Amylyx' clinical trial named Helios.

The HELIOS trial (NCT05676034) is a 12-participant, single-site, single-arm, open-label Phase 2 trial designed to evaluate the safety and tolerability of AMX0035 and various measures of endocrinologic, neurologic, and ophthalmologic function in adult participants living with Wolfram syndrome.

ABOUT WOLFRAM SYNDROME
Logo for Amylyx' clinical trial named Orion.

The ORION trial (NCT06122662) is a global, randomized, double-blind, placebo-controlled Phase 2b/3 clinical trial designed to assess the efficacy, safety, and tolerability of AMX0035 compared to placebo in people living with progressive supranuclear palsy (PSP).

ABOUT PSP
Logo for Amylyx' clinical trial named Lumina.

The LUMINA trial will be a multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose Phase 1 study evaluating the safety and biological activity of AMX0114 in 48 adult participants with ALS. LUMINA will also assess change from baseline in calpain-2 levels, neurofilament light chain (NfL) levels, and other pharmacodynamic biomarkers of ALS.

ABOUT ALS

New learnings from every data point

While we've learned a lot, our philosophy to clinical development is that we will always have more to discover. Every data point uncovers more as we improve our understanding of diseases so that we can develop better potential therapies.

ABOUT OUR SCIENCE